Roth MKM raised the firm’s price target on Viking Therapeutics to $19 from $15 and keeps a Buy rating on the shares. The analyst cites the company’s phase 1 clinical data for its metabolic disorder treatment VK2735, with key takeaways from this event said to include that the product was safe and tolerated and that its obesity profile was competitively favorable at one month of dosing. Viking intends to initiate a phase 2 study of subcutaneous VK2735 in patients with obesity in mid-2023, where higher doses likely will be evaluated, Roth MKM added.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VKTX:
- Viking Therapeutics price target raised to $35 from $12 at Raymond James
- Viking Therapeutics price target raised to $30 from $20 at Oppenheimer
- Stifel reiterates Buy on Viking Therapeutics, raises price target to $25
- Viking’s VK2735 looks like ‘heavyweight contender,’ says H.C. Wainwright
- VKTX Soars on Promising VK2735 Data
